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Abstract Lisdexamfetamine dimesylate (LDX) is a long-
acting, prodrug stimulant therapy for patients with atten-
tion-deficit/hyperactivity disorder (ADHD). This random-
ized placebo-controlled trial of an optimized daily dose of
LDX (30, 50 or 70 mg) was conducted in children and
adolescents (aged 6–17 years) with ADHD. To evaluate
the efficacy of LDX throughout the day, symptoms and
behaviors of ADHD were evaluated using an abbreviated
version of the Conners’ Parent Rating Scale-Revised
(CPRS-R) at 1000, 1400 and 1800 hours following early
morning dosing (0700 hours). Osmotic-release oral system
methylphenidate (OROS-MPH) was included as a refer-
ence treatment, but the study was not designed to support a
statistical comparison between LDX and OROS-MPH. The
full analysis set comprised 317 patients (LDX, n = 104;
placebo, n = 106; OROS-MPH, n = 107). At baseline,
CPRS-R total scores were similar across treatment groups. At
endpoint, differences (active treatment - placebo) in least
squares (LS) mean change from baseline CPRS-R total scores
were statistically significant (P \ 0.001) throughout the day
for LDX (effect sizes: 1000 hours, 1.42; 1400 hours, 1.41;
1800 hours, 1.30) and OROS-MPH (effect sizes: 1000 hours,
1.04; 1400 hours, 0.98; 1800 hours, 0.92). Differences in LS
mean change from baseline to endpoint were statistically
significant (P \ 0.001) for both active treatments in all four
subscales of the CPRS-R (ADHD index, oppositional,
hyperactivity and cognitive). In conclusion, improvements
relative to placebo in ADHD-related symptoms and behaviors
in children and adolescents receiving a single morning dose of
LDX or OROS-MPH were maintained throughout the day and
were ongoing at the last measurement in the evening
(1800 hours).
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) has an
estimated worldwide prevalence among children of 5.3 %
[1] and persists into adulthood in approximately two-thirds
of patients [2–4]. It is a well-defined disorder that is
characterized by persistent symptoms of hyperactivity,
impulsivity and/or inattention, which are associated with
serious impairments in academic, social and interpersonal
functioning [5, 6]. Stimulant medications are commonly
recommended as part of a comprehensive, multimodal
treatment plan for patients with ADHD that also includes
behavioral, psychoeducational and psychological inter-
ventions [7–10].
Lisdexamfetamine dimesylate (LDX) is the first chem-
ically formulated, long-acting, prodrug stimulant; the
active metabolite d-amfetamine is released enzymatically
from the parent molecule in the blood [11]. In clinical trials
conducted in the USA, LDX has been shown to be an
effective once-daily treatment for ADHD in children,
adolescents and adults [12–14]. The present study reports
secondary efficacy outcomes from the first European phase
3 clinical trial of LDX (SPD489-325). Study SPD489-325
was a randomized, double-blind, placebo-controlled trial
that evaluated the efficacy, safety and tolerability of dose-
optimized LDX over the course of 7 weeks in children and
adolescents aged 6–17 years with a diagnosis of ADHD
that was of at least moderate severity [15]. Compared with
placebo, the mean ADHD Rating Scale version IV
(ADHD-RS-IV) total score in patients treated with LDX
was significantly reduced from baseline to endpoint (effect
size 1.80), and 78 % of individuals receiving LDX dem-
onstrated clinically relevant improvements in Clinical
Global Impressions-Improvement (CGI-I) scores. Patients
receiving osmotic-release oral system methylphenidate
(OROS-MPH, included as a reference arm in this study)
also showed significant improvements in ADHD-RS-IV
total score (effect size 1.26) and CGI-I scores versus pla-
cebo. Both active treatments were well tolerated.
The duration of therapeutic effect is an important con-
sideration for clinicians when developing individualized
treatment plans for patients with ADHD. In North Ameri-
can study populations, the beneficial effects of LDX
treatment were reported to be ongoing at the last daily
time-point assessed (13 h post-dose in children and 14 h
post-dose in adults) [16, 17]. Here, we examine whether the
effects of LDX are maintained throughout the day (3, 7 or
11 h post-dose) in a European study of children and ado-
lescents with ADHD, using an abbreviated version of the
Conners’ Parent Rating Scale-Revised (CPRS-R) to eval-
uate ADHD-related symptoms and problem behaviors.
Methods
Patients and study design
The study protocol (ClinicalTrials.gov Identifier:
NCT00763971) was approved by an independent ethics
committee/institutional review board and regulatory
agency in each center (as appropriate). The study was
conducted in accordance with current international and
local applicable regulations, and written informed consent
was obtained from each participant or legally appointed
representative.
The design of this randomized, double-blind, parallel-
group, dose-optimized, placebo-controlled study has been
described in detail previously [15]. The study included a
reference arm comprising patients treated with an opti-
mized dose of OROS-MPH, but the study was not powered
to make inferential statistical comparisons between LDX
and OROS-MPH. Male and female children and adoles-
cents (aged 6–17 years) who satisfied the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision criteria [6] for a primary diagnosis of ADHD
were enrolled. Eligible patients had ADHD of at least
moderate severity (ADHD-RS-IV total score of 28 or
higher). The key exclusion criteria included failure to
respond, based on the investigators’ judgement, to an
adequate course (dose and duration) of OROS-MPH ther-
apy and patients with a documented allergy, hypersensi-
tivity or intolerance to amfetamine or methylphenidate.
Individuals with a comorbid psychiatric diagnosis with
significant symptoms (with the exception of oppositional
defiant disorder) and those with conduct disorder were
excluded. Patients whose current ADHD medication pro-
vided effective control of symptoms with acceptable tol-
erability were also excluded.
Eligible patients completed a screening and washout
period (3–42 days) and were randomized in a 1:1:1 ratio at
baseline (visit 0) to receive once-daily LDX (30, 50 or
70 mg), placebo or OROS-MPH (18, 36 or 54 mg) for a
7-week, double-blind evaluation period. This evaluation
period comprised a 4-week, stepwise dose-optimization
period (visits 1–4) and a 3-week dose-maintenance period
(visits 5–7). It was immediately followed by a 1-week
washout and post-treatment safety follow-up (visit 8/FU).
Patients who discontinued the study attended an early ter-
mination (ET) assessment (data obtained at this visit were
included in the visit 7/ET assessment) and a follow-up visit
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following a 1-week washout period (visit 8/FU). Unused
capsules (LDX, placebo or OROS-MPH) were returned and
accounted for prior to patients entering the washout period.
Dosing began (at approximately 0700 hours) on the day
after completion of the baseline visit (visit 0). Patients
initially received LDX 30 mg/day, placebo or OROS-MPH
18 mg/day. If an acceptable response was not achieved,
doses were increased in a stepwise manner at weekly
intervals at visits 1–3. ‘Acceptable response’ was defined
as at least a 30 % reduction in ADHD-RS-IV total score
from baseline and a CGI-I score of either 1 (very much
improved) or 2 (much improved), with tolerable adverse
effects. If a dose was well tolerated and the patient’s
symptoms could potentially be improved further, the dose
could be increased by one dose level. A reduction of one
dose level was permitted if individuals experienced an
intolerable adverse effect. Doses could be modified up to
but not after visit 3 and patients then continued to take their
individually optimized dose for the remainder of the dou-
ble-blind evaluation period (visits 4–7); patients unable to
tolerate the study treatment after this point were withdrawn
from the study.
Conners’ Parent Rating Scale-Revised
This study utilized an abbreviated version of the CPRS-R
(Multi-Health Systems Inc., North Tonawanda, NY, USA),
requiring feedback on 27 symptoms or problem behaviors
commonly exhibited by children and adolescents with
ADHD, which are grouped into four subscales: ADHD
index, oppositional, hyperactivity and cognitive [18]. A
parent (or legally appointed representative) gave the
symptom or behavior a score of 0–3 as follows: 0, not true
at all (never, seldom); 1, just a little true (occasionally); 2,
pretty much true (often, quite a bit); 3, very much true
(very often, very frequently). Therefore, the total score for
the entire scale ranged from 0 to 81. CPRS-R is typically
scored based on the patient’s behavior over the past month,
but for the purpose of this study, scoring was based on
behavior exhibited immediately before the assessment. A
decrease in CPRS-R total or subscale score represents an
improvement in ADHD symptoms and behaviors.
CPRS-R assessments were initially carried out on the
last weekend day before each study visit until a protocol
amendment limited assessments to the last weekend day
before the baseline visit, visit 4 (day 28) and visit 7 (day
49). To evaluate the duration of therapeutic effect at each
study visit and endpoint (defined as the last on-treatment,
post-baseline visit with a valid CPRS-R score), CPRS-R
assessments were performed at 1000, 1400 and 1800 hours
following a single morning dose (administered at approx-
imately 0700 hours). An overall CPRS-R score for each
visit was calculated by taking the mean of the three
assessments across the day. The present design does not
allow for measuring the treatment effect after 1800 hours.
Data analyses
CPRS-R assessments were carried out in the full analysis
set (FAS), defined as all patients who were randomized and
received at least one dose of investigational product.
Patients from one site (n = 15) were excluded owing to
violations of good clinical practice. Incomplete data
resulting from either early termination or unavailability
were handled by the approach of treatment endpoint anal-
ysis, in which ‘Endpoint’ is defined as the last on-treat-
ment, post-baseline visit with a valid CPRS-R score.
Statistical analyses included the calculation of least-
squares (LS) means and P values, which were based on
type III sum of squares from an analysis of covariance
(ANCOVA) model for the change from baseline, including
treatment, country and age groups as fixed effects and
baseline value as covariate. Effect sizes were calculated as
the difference between the LS mean scores for the active
treatment and placebo groups, divided by the root mean
square error obtained from the ANCOVA model. Effect
sizes of 0.2, 0.5 and 0.8 are considered to correspond to
small, medium and large magnitudes of effect, respectively
[19]. OROS-MPH was included in SPD489-325 as a ref-
erence arm. The purpose of this was to provide internal
validation of the study design and to facilitate interpreta-
tion of the data if the study drug (LDX) had failed to show
superiority over placebo. However, SPD489-325 was not
designed to support a formal statistical comparison
between LDX and OROS-MPH.
Results
Patient disposition and baseline demographics
As described previously [15], 336 patients were random-
ized, 317 were included in the FAS (LDX, n = 104; pla-
cebo, n = 106; OROS-MPH, n = 107) and 196 patients
completed the study (LDX, n = 80; placebo, n = 42;
OROS-MPH, n = 74). In all treatment arms, the most
commonly reported reason for discontinuing the study was
lack of efficacy (LDX, n = 11; placebo, n = 54; OROS-
MPH, n = 22). Baseline demographic and disease char-
acteristics, including mean age (standard deviation [SD])
(LDX, 10.9 [2.9] years; placebo, 11.0 [2.8] years; OROS-
MPH, 10.9 [2.6] years) and mean ADHD-RS-IV total score
(SD) (LDX, 41.0 [7.3]; placebo, 41.2 [7.2]; OROS-MPH
40.4 [6.8]), were similar among treatment groups [15].
Among patients who had a primary efficacy measure-
ment at endpoint, 26/104 (25.0 %) in the LDX group
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received the 30-mg dose at endpoint, 38/104 (36.5 %)
received 50 mg and 36/104 (34.6 %) received 70 mg. In
the OROS-MPH group, 17/107 (15.9 %) patients received
the 18-mg dose at endpoint, 22/107 (20.6 %) received
36 mg and 65/107 (60.7 %) received 54 mg.
CPRS-R total score by study visit
Although the protocol was amended during the study to
restrict the scheduled CPRS-R assessments to baseline,
visit 4 and visit 7, CPRS-R data were available for most of
the patients in each group for all visits (Fig. 1a). At base-
line, mean (standard error of the mean, SEM) CPRS-R total
scores were similar across treatment groups: LDX, 50.9
(1.6); placebo, 53.0 (1.5); OROS-MPH, 51.4 (1.7). In the
LDX treatment group, mean CPRS-R total scores
decreased during the study (Fig. 1a).The mean (SEM)
change from baseline to endpoint in CPRS-R total score
was -24.9 (1.8) for LDX and -5.0 (1.3) for placebo. The
difference in LS mean change from baseline [95 % confi-
dence interval (CI)] between LDX and placebo was sta-
tistically significant at endpoint [P \ 0.001, -21.3 (-25.5,
-17.0), effect size 1.41] and at each of the on-treatment
visits (Fig. 1b). In the OROS-MPH reference arm, the
mean (SEM) change from baseline to endpoint in CPRS-R
total score was -19.1 (2.1), and the difference in LS mean
change from baseline (95 % CI) between OROS-MPH and
placebo was statistically significant at endpoint [P \ 0.001,
-15.1 (-19.3, -10.9), effect size 1.00] and at visits 2–7
(P \ 0.05 for visit 6, P B 0.01 for visit 2 and P \ 0.001
for visits 3–5 and 7; Fig. 1b).
CPRS-R by time of day at endpoint
At baseline, mean CPRS-R total scores were within the
range 49–54 in all treatment groups and at all assessment
times (Fig. 2a). At endpoint, CPRS-R total scores were
lower throughout the day in patients treated with LDX than
in those treated with placebo (Fig. 2a). Differences in LS
mean change from baseline to endpoint (95 % CI) between
LDX and placebo were statistically significant (P \ 0.001)
throughout the day (1000 hours [-21.5 (-25.8, -17.1),
effect size 1.42]; 1400 hours [-22.1 (-26.7, -17.6), effect
size 1.41]; and 1800 hours [-21.2 (-25.8, -16.5), effect
size 1.30], (Fig. 2b). Differences in LS mean change from
baseline to endpoint between OROS-MPH and placebo
were also statistically significant (P \ 0.001) in the
morning (-15.6 [-20.0, -11.2], effect size 1.04), after-
noon (-15.3 [-19.7, -10.9], effect size 0.98) and evening
(-15.0 [-19.7, -10.3], effect size 0.92) (Fig. 2b).
Fig. 1 CPRS-R total score by study visit (full analysis set).
a Absolute values and b LS mean changes from baseline. The overall
CPRS-R total score for each visit was calculated as the mean of the
three assessments across the day. *P \ 0.05, **P B 0.01,
***P \ 0.001 versus placebo (based on the difference in LS mean
change [active treatment - placebo] from baseline to endpoint). Data
are presented as mean or LS mean change ± standard error of the
mean. Endpoint is the last on-treatment, post-baseline visit with a
valid CPRS-R score. Patients enrolled after a protocol amendment
had CPRS-R assessments at visits 0, 4 and 7/ET only. A decrease in
CPRS-R total score indicates an improvement in ADHD-related
symptoms and behaviors. ADHD attention-deficit/hyperactivity dis-
order, CPRS-R Conners’ Parent Rating Scale-Revised, ET early
termination, FU follow-up, LDX lisdexamfetamine dimesylate, LS
least-squares, OROS-MPH osmotic-release oral system
methylphenidate
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CPRS-R subscales
Differences in LS mean change from baseline to endpoint
between LDX and placebo were statistically significant
(P \ 0.001) for all four CPRS-R subscale scores (ADHD
index, oppositional, hyperactivity and cognitive) averaged
across the day (Table 1). Similarly, differences in LS mean
from baseline to endpoint between OROS-MPH and pla-
cebo were statistically significant (P \ 0.001) in all four
subscales (Table 1).
Post hoc comparison of LDX and OROS-MPH based
on CPRS-R total scores
A statistical comparison between LDX and OROS-MPH
was not pre-specified in the SPD489-325 study design.
When assessed post hoc, differences in LS mean change
from baseline to endpoint (95 % CI) between LDX and
OROS-MPH were statistically significant (P \ 0.05), in
favor of LDX, at 1000 hours (-5.8 [-10.3, -1.4], effect
size 0.387), 1400 hours (-6.8 [-11.4, -2.3], effect size
0.435) and 1800 hours (-6.1 [-10.9, -1.4], effect size
0.377).
Discussion
Lisdexamfetamine dimesylate (LDX) was significantly
more effective than placebo in reducing symptoms and
problem behaviors in children and adolescents with ADHD
throughout the 7-week course of this phase 3 study, as
assessed using the abbreviated version of the CPRS-R. At
endpoint, improvements versus placebo in CPRS-R total
score were maintained throughout the day and were
ongoing at the last assessment of the day (1800 hours)
following a single early morning dose (0700 hours), and
benefits were observed across all four CPRS-R subscales
(ADHD index, oppositional, hyperactivity and cognitive).
Treatment benefits were also observed in the OROS-MPH
reference arm, and these were also maintained throughout
the day and spanned all four CPRS-R subscales. Stimulant
medications, as well as the non-stimulant atomoxetine, are
highly effective treatments for ADHD symptoms [20–22].
ADHD symptoms impact the full waking day [23]; hence,
the therapeutic duration of action is a primary consider-
ation in ADHD medication choice. Long-acting medica-
tions are reported to offer improved convenience,
confidentiality, adherence, pharmacokinetic coverage and
reduced abuse potential, compared with short-acting
counterparts [7, 22, 24, 25].
The prodrug LDX is therapeutically inactive and requires
enzymatic cleavage in the blood to yield the active moiety,
d-amfetamine [11]. Human pharmacokinetic studies indi-
cate that, after oral administration of LDX, exposure to
d-amfetamine is long lasting and dose proportional, with low
inter- and intra-individual variability [26, 27]. In the present
study, the efficacy of an optimized dose of LDX was eval-
uated via CPRS-R assessments conducted at three time-
points throughout the day. Statistically significant differ-
ences between LDX and placebo in LS mean change from
baseline to endpoint in CPRS-R total score were observed at
all assessment time-points up to and including 1800 hours,
following a single early morning dose (0700 hours) of LDX.
Fig. 2 CPRS-R total score at baseline and endpoint by time of day
(full analysis set). a Absolute CPRS-R total scores at baseline and
endpoint and b LS mean changes from baseline to endpoint in CPRS-
R total score by time of day. ***P \ 0.001 versus placebo, based on
the difference in LS mean change (active treatment - placebo) from
baseline to endpoint. Data are presented as mean or LS mean
change ± standard error of the mean. Dosing occurred at approxi-
mately 0700 hours. Endpoint is the last on-treatment, post-baseline
visit with a valid CPRS-R score. Patients enrolled after a protocol
amendment had CPRS-R assessments at visits 0, 4 and 7/ET only. A
decrease in CPRS-R total score indicates an improvement in ADHD-
related symptoms and behaviors. ADHD attention-deficit/hyperactiv-
ity disorder, CPRS-R Conners’ Parent Rating Scale-Revised, ET early
termination, FU follow-up, LDX lisdexamfetamine dimesylate,
OROS-MPH osmotic-release oral system methylphenidate
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The CPRS-R total score effect size of 1.30 at the final
assessment of the day further suggests that the therapeutic
benefit of LDX remains robust for at least 11 h post-dose.
However, as the last time-point assessed in the day was at
18.00 h, the design of this study does not allow the duration
of effect beyond the 11 h post-dose time-point to be
determined.
Results from this first evaluation of LDX in a European
sample correspond well with evidence of the long duration
of action of LDX derived from North American studies. In
the pivotal US study of LDX in children with ADHD,
statistically significant differences between LDX and pla-
cebo in change from baseline in CPRS-R total score were
also ongoing at 1800 hours, following once-daily admin-
istration in all three fixed-dose groups (30, 50 and 70 mg)
[13]. Further evidence of a long duration of action of LDX
comes from a laboratory school study in children with
ADHD, in which the efficacy of LDX was maintained for
at least 13 h post-dose, as determined by the Swanson,
Kotkin, Agler, M-Flynn and Pelham-Attention (SKAMP-
A) and -Deportment (SKAMP-D) scales and the Permanent
Product Measure of Performance-Attempted (PERMP-A)
and -Correct (PERMP-C) scales [16].
The primary efficacy measure of study SPD489-325 was
the clinician-rated ADHD-RS-IV, which revealed robust
treatment benefits of LDX at endpoint (mean ADHD-RS-
IV total score effect size, 1.80). As a parent-rated scale, the
CPRS-R complements the ADHD-RS-IV by monitoring
ADHD symptoms and problem behaviors outside the
clinic, in a range of academic (e.g., homework), social and
domestic settings. The value of parent-rated assessments of
ADHD symptoms and behaviors is well established [28].
The CPRS was introduced in 1970, and subsequently
revised to improve the psychometric properties of the tool
[18]. Our observation that patients receiving LDX dem-
onstrated robust improvements across all four subscales of
the abbreviated version of the CPRS-R suggests that LDX
is effective across a broad range of parent-rated symptom
and behavioral domains of ADHD. The large effect sizes
obtained in study SPD489-325 for LDX on the CPRS-R
(present study) and ADHD-RS-IV [15] are consistent with
a previous North American study (range 1.21–1.60) [13]
and indicate robust treatment efficacy. It is possible that the
relatively small response to placebo in study SPD489-325
also contributed, at least in part, to these large treatment
effects.
While the present study did not include an evaluation of
subscale scores throughout the day, the US-based, forced-
dose, phase 3 clinical trial of LDX in children reported
significant improvements in scores of the ADHD index,
hyperactivity and cognitive subscales of the CPRS-R at all
three assessment times (1000, 1400 and 1800 hours),
irrespective of dose [29]. Improvements in the oppositional
subscale were significant in all patients treated with LDX at
the morning and afternoon assessments only, but were
maintained until 1800 hours in the subgroup of patients
receiving LDX who had the highest CGI-Severity of Illness
scores at baseline (in the range 5–7) [29].
In the present study, OROS-MPH was included as a
reference arm. With the exception of the first post-treat-
ment visit (week 1), statistically significant differences
versus placebo in LS mean change from baseline in CPRS-
R total score were observed in the OROS-MPH treatment
group at all visits, with an effect size at endpoint of 1.00.
Table 1 Change from baseline
to endpoint in CPRS-R subscale
scores (full analysis set)
n is the number of patients with
a valid CPRS-R subscale score
at baseline. A decrease in
CPRS-R subscale scores
represents an improvement in
ADHD-related symptoms and
behaviors. The overall CPRS-R
score for each visit was
calculated as the mean of the
three assessments across the day
ADHD attention-deficit/
hyperactivity disorder, CI
confidence interval, CPRS-R
Conners’ Parent Rating Scale-
Revised, LDX lisdexamfetamine
dimesylate, LS least-squares,
OROS-MPH osmotic-release
oral system methylphenidate,
SD standard deviation
Subscale Baseline,
mean (SD)
Difference (active treatment
- placebo) in LS mean
change (95 % CI)
P value (active
treatment vs. placebo)
Effect
size
ADHD index
LDX (n = 99) 25.5 (7.16) -11.0 (-13.0, -9.0) \0.001 1.54
Placebo (n = 102) 25.9 (7.13)
OROS-MPH (n = 103) 24.9 (7.93) -7.0 (-9.0, -5.0) \0.001 0.98
Oppositional
LDX (n = 100) 10.3 (5.09) -3.5 (-4.6, -2.5) \0.001 0.95
Placebo (n = 103) 10.5 (4.35)
OROS-MPH (n = 104) 10.0 (5.19) -2.6 (-3.7, -1.6) \0.001 0.71
Hyperactivity
LDX (n = 98) 9.0 (5.30) -4.4 (-5.4, -3.4) \0.001 1.22
Placebo (n = 102) 10.0 (4.65)
OROS-MPH (n = 100) 10.3 (5.01) -3.9 (-4.9, -2.9) \0.001 1.07
Cognitive
LDX (n = 97) 12.9 (4.11) -5.0 (-6.2, -3.8) \0.001 1.21
Placebo (n = 101) 13.2 (4.24)
OROS-MPH (n = 97) 12.9 (4.37) -2.9 (-3.3, -0.9) \0.001 0.70
Eur Child Adolesc Psychiatry
123
Improvements versus placebo in LS mean change from
baseline in CPRS-R total score were evident throughout the
day in the OROS-MPH group. Furthermore, improvements
were observed across all four CPRS-R subscales. The
observed efficacy of OROS-MPH supports the validity and
sensitivity of the study design. However, the statistical
protocol for this study did not pre-specify a formal statis-
tical comparison between the two active treatments and any
comparison of the relative effects of LDX and OROS-MPH
must, therefore, be considered exploratory.
Among the key strengths of this study are its random-
ized, double-blind, placebo-controlled design, the inclusion
of an OROS-MPH reference arm, and a European patient
population that included both children (aged 6–12 years)
and adolescents (aged 13–17 years). The results should,
however, be interpreted in the light of several consider-
ations. First, the highly homogeneous study population,
from which patients with a range of comorbid diagnoses
were excluded, may not reflect a typical cross section of
patients with ADHD who are seen in clinical practice.
Secondly, while these data indicate that the efficacy of
LDX and OROS-MPH is maintained at 1800 hours fol-
lowing a single early morning dose, they do not indicate
the maximum therapeutic duration of action of either active
treatment, which may have extended beyond this time-
point. Finally, although effect sizes relative to placebo
were numerically greater for LDX than for OROS-MPH,
the study was not powered for inferential statistical com-
parisons between LDX and OROS-MPH, and because the
dose-optimized design of the study precluded any estima-
tion of dose-equivalence, comparisons of the two active
treatment arms must be qualitative and tentative.
In conclusion, improvements versus placebo in ADHD-
related symptoms and problem behaviors in children and
adolescents with ADHD receiving a single early morning
dose (0700 hours) of LDX or OROS-MPH were robust
throughout the day and were ongoing in the early evening
(1800 hours).
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